Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Pediatr Allergy Immunol. 2020 Feb;31 Suppl 24:40-42. doi: 10.1111/pai.13168.
Severe asthma in children is considered a complex and heterogeneous disease. A multidisciplinary assessment is required to correctly identify and manage these children because they potentially need close monitoring and additional treatment with advanced targeted therapies. Recent research efforts focused on the identification of epidemiologic, clinical, and functional characteristics of the disease in the pediatric age. Novel findings on the molecular mechanisms underlying severe asthma have led to the recognition of different endotypes and related biomarkers able to predict the response to advanced biologic therapies. Progress in our knowledge of severe asthma has occurred with the introduction of biologic therapies. Future goals in asthma care include the identification of the links between phenotypes and endotypes, as well as the identification of novel predictive biomarkers. They will help to select candidates for innovative biologic therapies and ultimately improve outcomes in children with severe asthma.
儿童重症哮喘被认为是一种复杂且异质性的疾病。为了正确识别和管理这些儿童，需要进行多学科评估，因为他们可能需要密切监测，并额外使用先进的靶向治疗。最近的研究工作集中在确定儿科年龄的疾病的流行病学、临床和功能特征。重症哮喘的分子机制的新发现导致了不同的表型和相关生物标志物的识别，这些标志物能够预测对先进的生物治疗的反应。生物治疗的引入使我们对重症哮喘的认识取得了进展。未来的哮喘治疗目标包括确定表型和内型之间的联系，以及确定新的预测生物标志物。它们将有助于为创新的生物治疗选择候选者，并最终改善重症哮喘儿童的预后。
